NASDAQ:VCYT

Veracyte Announces First Quarter 2024 Financial Results

Retrieved on: 
Tuesday, May 7, 2024
Technology, Health Technology, Software, Biometrics, Biotechnology, Pharmaceutical, Health, Data Management, Oncology, Artificial Intelligence, Table, GAAP, Prostate, NCCN, Investment, MRD, Abstract, National Comprehensive Cancer Network, Webcast, JCO, Growth, Prostate cancer, Patient, Acquisition, Medicare, Metabolism, Genomics, Annual general meeting, Waiting, Endocrinology, Bladder cancer, Journal

Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2024.
  • Total revenue for the first quarter of 2024 was $96.8 million, an increase of 17% compared to $82.4 million reported in the first quarter of 2023.
  • Net loss for the first quarter of 2024 was $1.9 million, an improvement of 77% compared to the first quarter of 2023.
  • Veracyte will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss the company's financial results and provide a general business update.

14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding

Retrieved on: 
Monday, May 6, 2024
Oncology, Health, Technology, Health Technology, Genetics, Artificial Intelligence, Biotechnology, RUO, University, Prostate, NCCN, RC, International, RP, Risk, Grade, American Urological Association, Survival, Neoadjuvant therapy, PSA, Columbia University, Integration, Research, Pathology, GSC, Prostate cancer, Prostate-specific antigen, University of Michigan, Patient, NOC, Urology, Intelligence, AUA, MRI, Biopsy, Gene expression, Diagnosis, MUSIC, Waiting, Bladder cancer, Radical, Medical imaging

(Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the annual meeting of the American Urological Association, show that the Decipher Prostate and Decipher Bladder Genomic Classifiers provide better prognostic information for patients with prostate and bladder cancer, compared to standard approaches.

Key Points: 
  • (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the annual meeting of the American Urological Association, show that the Decipher Prostate and Decipher Bladder Genomic Classifiers provide better prognostic information for patients with prostate and bladder cancer, compared to standard approaches.
  • They also show that the research-use-only Decipher GRID (Genomic Resource for Intelligent Discovery) tool is helping to advance scientific understanding of these diseases.
  • Summary: The Decipher Prostate Genomic Classifier is associated with adverse pathology in patients eligible for Active Surveillance (AS) who were treated with radical prostatectomy (RP).
  • Podium Presentation PD42-03 : Understanding Population-Wide Genomic Risk Distribution and Integrating Clinical-Genomic Risk for Prognostication in Prostate Cancer.

New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance

Retrieved on: 
Monday, April 22, 2024
Oncology, Data Management, Health, Technology, Health Technology, Software, Biotechnology, Radiation, Patient, Prostate, Risk, Safety, JCO, MVA, Prostate cancer, Disease, Urology, Intelligence, Neoplasm, Biomarker, Waiting, GRID, Medical imaging

(Nasdaq: VCYT), a leading cancer diagnostics company, today announced that a new study published in JCO Precision Oncology shows that, among patients undergoing Active Surveillance (AS) for prostate cancer, the Decipher Prostate Genomic Classifier is prognostic for identifying those whose disease is likely to progress.

Key Points: 
  • (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that a new study published in JCO Precision Oncology shows that, among patients undergoing Active Surveillance (AS) for prostate cancer, the Decipher Prostate Genomic Classifier is prognostic for identifying those whose disease is likely to progress.
  • The findings make the Decipher test the only gene expression test to have treatment-outcome data from a prospective, multi-center, phase 2, randomized trial in the AS population.
  • “The findings from the ENACT trial analysis demonstrate that the Decipher Prostate test is a predictor of disease progression on AS,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology.
  • The findings also demonstrated the use of Decipher GRID (Genomic Resource for Intelligent Discovery) as a research tool to help advance scientific understanding of prostate cancer.

Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024

Retrieved on: 
Monday, April 22, 2024
Technology, Biotechnology, Health, Biometrics, Professional Services, Artificial Intelligence, Oncology, Research, Software, Data Analytics, Genetics, Health Technology, Science, Data Management

Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2024 after the close of market on Tuesday, May 7, 2024.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2024 after the close of market on Tuesday, May 7, 2024.
  • Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
  • The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/6m9ec99y .
  • A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations .

Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024

Retrieved on: 
Tuesday, April 16, 2024
Science, Biotechnology, Research, Oncology, Public Relations, Investor Relations, General Health, Health, Communications, American Urological Association, Abstract, Biology, Prostate, Patient, Urology, AUA, GRID

(Nasdaq: VCYT), a leading cancer diagnostics company, today announced that nine abstracts focused on its Decipher Prostate and Decipher Bladder Genomic Classifiers will be presented at AUA 2024, the annual meeting of the American Urological Association, taking place May 3-6 in San Antonio.

Key Points: 
  • (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that nine abstracts focused on its Decipher Prostate and Decipher Bladder Genomic Classifiers will be presented at AUA 2024, the annual meeting of the American Urological Association, taking place May 3-6 in San Antonio.
  • Studies to be presented include those that evaluate the clinical utility of the company’s Decipher tests in guiding treatment decisions for patients with prostate or bladder cancer.
  • Other presentations will explore new insights into these cancers’ underlying biology, which researchers derived through use of Veracyte’s whole-transcriptome-based Decipher GRID research tool.
  • “The data being presented at AUA 2024 expands the extensive clinical evidence supporting our Decipher Prostate and Decipher Bladder tests,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology.

Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines

Retrieved on: 
Tuesday, February 27, 2024
Software, Research, Professional Services, Oncology, Biometrics, Technology, Medical Devices, Artificial Intelligence, Health Technology, Data Analytics, Science, Biotechnology, Health, Clinical trial, Risk, Disease, Prostate, Criterion, Biomarker, NCCN, Classification, Prostate cancer, Patient, 1B, Medical imaging

(Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene expression test to receive a “Level 1B” evidence rating in the 2024 NCCN* Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a prognostic tool for the risk stratification of patients with localized prostate cancer.

Key Points: 
  • (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene expression test to receive a “Level 1B” evidence rating in the 2024 NCCN* Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a prognostic tool for the risk stratification of patients with localized prostate cancer.
  • Level 1B was assigned to Decipher Prostate based on the evidence in both the post-biopsy and post-prostatectomy settings.
  • Additionally, because of this classification, the Decipher Prostate test is the only gene expression test for which the guidelines synthesize the available published data in a separate table that summarizes treatment implications for patients based on both their NCCN risk classification and Decipher score.
  • They summarize the treatment implications for patients based on their Decipher score and the published evidence from analyses of multiple randomized, phase 3 clinical trials.

Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Thursday, February 22, 2024
Software, Internet, Oncology, Health, Artificial Intelligence, Data Management, Health Technology, Technology, Acquisition, Endocrinology, Prostate cancer, Investment, 2005 in television, Table, NGS, GAAP, Level 1, TERT, NCCN, Webcast, Abstract, Patient, MRD, Prostate, Publication, Genomics, IVD, Video game

Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2023.
  • “We closed 2023 with another quarter of excellent results, driven by our Afirma and Decipher businesses,” said Marc Stapley, Veracyte’s chief executive officer.
  • Total revenue for the fourth quarter of 2023 was $98.2 million, an increase of 22% compared to $80.3 million reported in the fourth quarter of 2022.
  • Total gross margin for the fourth quarter of 2023, including the amortization of acquired intangible assets, was 66%, compared to 61% in the fourth quarter of 2022.

Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference

Retrieved on: 
Wednesday, February 21, 2024
Software, Research, Professional Services, Oncology, Technology, Artificial Intelligence, Genetics, Health Technology, Data Analytics, Science, Biotechnology, Health, Doctor of Philosophy, Webcast, CLIA, Conference

Veracyte, Inc .

Key Points: 
  • Veracyte, Inc .
  • (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and John Leite, Ph.D., chief commercial officer, CLIA, will present at the Raymond James 45th Annual Institutional Investors Conference on Monday, March 4, 2024, at 9:50 a.m. Eastern Time.
  • A live audio webcast of the company’s presentation will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations .
  • A replay of the webcast will be available for 90 days following the conclusion of the live broadcast.

Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

Retrieved on: 
Thursday, February 8, 2024
Technology, Biotechnology, Health, Biometrics, Professional Services, Artificial Intelligence, Oncology, Research, Software, Data Analytics, Genetics, Health Technology, Science, Data Management

Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the fourth quarter and full-year 2023 after the close of market on Thursday, February 22, 2024.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the fourth quarter and full-year 2023 after the close of market on Thursday, February 22, 2024.
  • Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
  • The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/tkiac6t9 .
  • A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations .

Veracyte Completes Acquisition of C2i Genomics

Retrieved on: 
Tuesday, February 6, 2024
Software, Research, General Health, Networks, Pharmaceutical, Data Management, Oncology, Technology, Genetics, Artificial Intelligence, Science, Biotechnology, Health, Genomics, Risk assessment, MRD, Patient, Diagnosis, Acquisition, Medical imaging

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it has completed its acquisition of C2i Genomics, Inc., adding whole-genome minimal residual disease (MRD) capabilities to its novel diagnostics platform and expanding the company’s ability to serve patients across the cancer care continuum.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it has completed its acquisition of C2i Genomics, Inc., adding whole-genome minimal residual disease (MRD) capabilities to its novel diagnostics platform and expanding the company’s ability to serve patients across the cancer care continuum.
  • “Bringing C2i Genomics’ technology and team into Veracyte will allow us to make significant advances in our vision to transform cancer care for patients all over the world,” said Marc Stapley, Veracyte’s chief executive officer.
  • Under terms of the transaction, Veracyte acquired C2i Genomics for $70 million (subject to customary purchase price adjustments), paid for with 2.7 million Veracyte shares.
  • Veracyte will pay up to an additional $25 million, payable in Veracyte shares or cash at Veracyte’s election, based on the achievement of future performance milestones over the next two years.